关注
David Yeung
David Yeung
Precision Medicine, SAHMRI, Adelaide
在 adelaide.edu.au 的电子邮件经过验证
标题
引用次数
引用次数
年份
Safety and efficacy of imatinib cessation for CML patients with stable undetectable minimal residual disease: results from the TWISTER study
DM Ross, S Branford, JF Seymour, AP Schwarer, C Arthur, DT Yeung, ...
Blood, The Journal of the American Society of Hematology 122 (4), 515-522, 2013
8492013
Asciminib in chronic myeloid leukemia after ABL kinase inhibitor failure
TP Hughes, MJ Mauro, JE Cortes, H Minami, D Rea, DJ DeAngelo, ...
New England Journal of Medicine 381 (24), 2315-2326, 2019
3592019
Prognosis for patients with CML and >10% BCR-ABL1 after 3 months of imatinib depends on the rate of BCR-ABL1 decline
S Branford, DT Yeung, WT Parker, ND Roberts, L Purins, JA Braley, ...
Blood, The Journal of the American Society of Hematology 124 (4), 511-518, 2014
2242014
Early molecular response and female sex strongly predict stable undetectable BCR-ABL1, the criteria for imatinib discontinuation in patients with CML
S Branford, DT Yeung, DM Ross, JA Prime, CR Field, HK Altamura, ...
Blood, The Journal of the American Society of Hematology 121 (19), 3818-3824, 2013
2222013
Production, safety and efficacy of iPSC-derived mesenchymal stromal cells in acute steroid-resistant graft versus host disease: a phase I, multicenter, open-label, dose …
AJC Bloor, A Patel, JE Griffin, MH Gilleece, R Radia, DT Yeung, D Drier, ...
Nature medicine 26 (11), 1720-1725, 2020
2132020
Integrative genomic analysis reveals cancer-associated mutations at diagnosis of CML in patients with high-risk disease
S Branford, P Wang, DT Yeung, D Thomson, A Purins, C Wadham, ...
Blood, The Journal of the American Society of Hematology 132 (9), 948-961, 2018
1822018
TIDEL-II: first-line use of imatinib in CML with early switch to nilotinib for failure to achieve time-dependent molecular targets
DT Yeung, MP Osborn, DL White, S Branford, J Braley, A Herschtal, ...
Blood, The Journal of the American Society of Hematology 125 (6), 915-923, 2015
1082015
Long-term treatment-free remission of chronic myeloid leukemia with falling levels of residual leukemic cells
DM Ross, IS Pagani, N Shanmuganathan, CH Kok, JF Seymour, AK Mills, ...
Leukemia 32 (12), 2572-2579, 2018
782018
The impact of multiple low-level BCR-ABL1 mutations on response to ponatinib
WT Parker, DTO Yeung, AL Yeoman, HK Altamura, BA Jamison, CR Field, ...
Blood, The Journal of the American Society of Hematology 127 (15), 1870-1880, 2016
732016
The clinical significance of ABCB1 overexpression in predicting outcome of CML patients undergoing first-line imatinib treatment
LN Eadie, P Dang, VA Saunders, DT Yeung, MP Osborn, AP Grigg, ...
Leukemia 31 (1), 75-82, 2017
692017
Successful treatment‐free remission in chronic myeloid leukaemia and its association with reduced immune suppressors and increased natural killer cells
YD Irani, A Hughes, J Clarson, CH Kok, N Shanmuganathan, DL White, ...
British Journal of Haematology 191 (3), 433-441, 2020
632020
TGF-α and IL-6 plasma levels selectively identify CML patients who fail to achieve an early molecular response or progress in the first year of therapy
E Nievergall, J Reynolds, CH Kok, DB Watkins, M Biondo, SJ Busfield, ...
Leukemia 30 (6), 1263-1272, 2016
622016
Early BCR-ABL1 kinetics are predictive of subsequent achievement of treatment-free remission in chronic myeloid leukemia
N Shanmuganathan, IS Pagani, DM Ross, S Park, ASM Yong, JA Braley, ...
Blood, The Journal of the American Society of Hematology 137 (9), 1196-1207, 2021
612021
High prevalence of relapse in children with Philadelphia-like acute lymphoblastic leukemia despite risk-adapted treatment
SL Heatley, T Sadras, CH Kok, E Nievergall, K Quek, P Dang, B McClure, ...
Haematologica 102 (12), e490, 2017
602017
BCR-ABL1 doubling times more reliably assess the dynamics of CML relapse compared with the BCR-ABL1 fold rise: implications for monitoring and management
S Branford, DT Yeung, JA Prime, SY Choi, J Bang, JE Park, DW Kim, ...
Blood, The Journal of the American Society of Hematology 119 (18), 4264-4271, 2012
582012
Differential effects on gene transcription and hematopoietic differentiation correlate with GATA2 mutant disease phenotypes
CE Chong, P Venugopal, PH Stokes, YK Lee, PJ Brautigan, DTO Yeung, ...
Leukemia 32 (1), 194-202, 2018
562018
Lineage of measurable residual disease in patients with chronic myeloid leukemia in treatment-free remission
IS Pagani, P Dang, VA Saunders, R Grose, N Shanmuganathan, CH Kok, ...
Leukemia 34 (4), 1052-1061, 2020
442020
KMT2A rearranged acute lymphoblastic leukaemia: Unravelling the genomic complexity and heterogeneity of this high-risk disease
MO Forgione, BJ McClure, LN Eadie, DT Yeung, DL White
Cancer letters 469, 410-418, 2020
422020
Consumer engagement in health care policy, research and services: A systematic review and meta-analysis of methods and effects
LK Wiles, D Kay, JA Luker, A Worley, J Austin, A Ball, A Bevan, M Cousins, ...
PloS one 17 (1), e0261808, 2022
402022
The incidence and natural history of dasatinib complications in the treatment of chronic myeloid leukemia
LC Fox, KD Cummins, B Costello, D Yeung, R Cleary, C Forsyth, ...
Blood advances 1 (13), 802-811, 2017
382017
系统目前无法执行此操作,请稍后再试。
文章 1–20